Abstract:Abstract Background Experimental, clinical, and genetic epidemiological studies continue clarifying important aspects of Alzheimer’s disease (AD) pathological development. Despite this progress the genetic mechanisms of AD regulation remain unclear. One problem that may contribute to slowing further progress in better understanding of these mechanisms deals with difficulties in replication of the results of genetic association studies. To overcome this problem the idea of using a gene‐based analysis in which all common variation within a candidate gene is considered jointly has been suggested. In this paper we investigate to what extent the use of gene‐based analyses resolves the non‐replication problem. Method We performed gene‐level and meta‐analysis association studies for two cohorts: Cardiovascular Heart Study (CHS) and Framingham (FRAM) using Alzheimer’s disease as a primary outcome. To support our findings, we also performed meta‐analysis following gene‐enrichment study for both cohorts. Analysis was performed separately for males and females and for both sexes. Additional covariates were age, smoking. Gene‐level analysis was performed with fastBAT and enrichment analysis with ClusterProfiler on KEGG database. Result Our analysis identified a list of highly significant genes, such as TOMM40, APOC1 (all with FDR‐adjusted p‐value < 0.05) and pathways, such as Cholesterol metabolism, Fluid shear stress and atherosclerosis, Proteoglycans in cancer, Lipid and atherosclerosis showed statistically significant associations (FDR‐adjusted p‐value < 0.05) in both datasets and sexes. Meta‐analysis revealed TOMM40 (p‐value = 2.35E‐16), APOC1 (p‐value 4.46E‐13), ENSG00000259648 (p‐value = 8.88E‐06), PEX7 (p‐value = 4.40E‐05), ENSG00000287274 (p‐value = 5.38E‐05) genes for men and women combined; men exclusively revealed ENSG00000259648, TOMM40, and APOC1 (p‐value<1.75E‐05) and women TOMM40 and APOC1 (p‐value<6E‐08). Gene‐enrichment meta‐analysis revealed NOD‐like receptor signaling pathway (adjusted p‐value 3.23E‐07), Lipid and atherosclerosis (p‐value = 5.93E‐05), Yersinia (p‐value = 1.17E‐04) for men and women combined; for men only the pathways are Lipid and atherosclerosis (p‐value = 3.61E‐03), TGF‐beta signaling pathway (p‐value = 3.61E‐03), AGE‐RAGE signaling pathway in diabetic complications (p‐value = 5.18E‐03); and for women Cholesterol metabolism (p‐value = 3.49E‐07), Fatty acid degradation (p‐value = 1.04E‐06), PPAR signaling pathway (p‐value = 1.23E‐05). Conclusion In this work we were able to identify statistically significant genes and pathways showed replication across the studies and are potentially useful for uncovering genetic mechanisms of AD. However, other things such as genetic heterogeneity may influence disease developing and needed further exploration.

Pervasive biases in proxy genome-wide association studies based on parental history of Alzheimer's disease

A Bidirectional Mendelian Randomization Study Negates Causal Effects of Parkinson, Alzheimer on Basal Cell Carcinoma

A cautionary tale for Alzheimer's disease GWAS by proxy

GWAS on family history of Alzheimer’s disease

Interpretation of 10 years of Alzheimer's disease genetic findings in the perspective of statistical heterogeneity

Validating Gwas-Identified Risk Loci for Alzheimer'S Disease in Han Chinese Populations

Proteome-wide association studies using summary pQTL data of three tissues identified 30 risk genes of Alzheimer's disease dementia

Identification of 16 novel Alzheimer's disease susceptibility loci using multi-ancestry meta-analyses of clinical Alzheimer's disease and AD-by-proxy cases from four whole genome sequencing datasets

X-Chromosome-wide association study for Alzheimer’s disease

Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk

Family History of AD/Dementia, Polygenic Risk Score for AD, and Parkinson's Disease

Gene‐level Association Study of Alzheimer’s Disease on CHS and FRAM cohorts

Biobank-wide association scan identifies risk factors for late-onset Alzheimer's disease and endophenotypes

Biobank-wide association scan identifies risk factors for late-onset Alzheimer’s disease and endophenotypes

Pitfall of genome-wide association studies: Sources of inconsistency in genotypes and their effects

X‐chromosome-wide association study for Alzheimer's disease

Genome-wide association studies for Alzheimer’s disease: bigger is not always better

Interpreting disease genome‐wide association studies and polygenetic risk scores given eligibility and study design considerations

Polygenic Liability to Alzheimer's Disease Is Associated with a Wide Range of Chronic Diseases: A Cohort Study of 312,305 Participants

Polygenic Liability to Alzheimer’s Disease is Associated with a Wide Range of Chronic Diseases: A Cohort Study of 312,305 Participants

A Phenome-wide Association and Mendelian Randomization Study for Alzheimer?s Disease: A Prospective Cohort Study of 502,493 Participants From the UK Biobank